Named Bioactive Compounds · Compound
Furosin
Moderate Evidenceflavonoid2 PubMed Studies
Hermetica Superfood Encyclopedia
Furosin is a furanoflavonoid glycoside belonging to the flavonoid class of polyphenolic compounds, structurally characterized by a furan ring fused to the flavonoid backbone. Current scientific literature contains no human clinical trials or documented pharmacological data establishing any therapeutic mechanism or health application for this compound.
Furosin is a complex polyphenolic glycoside with the molecular formula C27H22O19, featuring a β-D-glucopyranose core linked to a benzoxocin derivative with multiple hydroxy and carboxylate groups. While its chemical class aligns with plant-derived glycosides potentially from traditional herbal sources, no specific natural source organism, plant origin, or extraction method has been documented.
No clinical evidence exists for furosin in human trials, RCTs, or meta-analyses. No PubMed PMIDs or studies on efficacy, sample sizes, or outcomes were identified in available sources.
No clinically studied dosage ranges, forms, or standardization details are available as no human studies exist. Consult a healthcare provider before starting any new supplement.
Furosin is a compound (also referred to as furosine, epsilon-N-(2-furoylmethyl)-L-lysine) formed as a Maillard reaction intermediate during the acid hydrolysis of Amadori compounds (specifically fructoselysine derived from the reaction between reducing sugars and the epsilon-amino group of lysine residues in proteins). It is not a nutrient or food ingredient itself, but rather an analytical marker compound. Key details: • It is a modified amino acid derivative with a molecular formula of C₁₂H₁₈N₂O₄ (MW ~254.28 g/mol). • It contains a furan ring conjugated to a lysine backbone via a methyl-carbonyl linkage. • No macronutrient value (not a source of carbohydrates, fats, or usable protein). • No micronutrient content (no vitamins or minerals). • No bioactive compounds of nutritional relevance at physiological concentrations. • Furosin/furosine is detected in heat-processed foods (e.g., UHT milk, dried milk powder, baked goods, roasted coffee) at levels typically ranging from ~1–300 mg/100 g protein depending on the severity of thermal processing. • Its presence is used as an indicator of lysine blockage (loss of bioavailable lysine), meaning higher furosine levels in a food correlate with reduced nutritional quality of the protein due to Maillard-induced lysine damage. • Bioavailability: Furosin itself is not intentionally consumed for nutritional benefit; it is largely excreted in urine and serves as an indirect biomarker of dietary exposure to early Maillard reaction products. It has no established absorption, distribution, or metabolic pathway associated with nutritional function. • No established Dietary Reference Intake, Recommended Daily Allowance, or tolerable upper intake level exists for this compound.
Furosin's precise molecular mechanism of action has not been established in peer-reviewed pharmacological literature. As a furanoflavonoid glycoside, it is structurally hypothesized to share partial characteristics with related compounds such as psoralen and isopsoralen, which interact with cytochrome P450 enzymes and DNA photoadducts, but no receptor-binding, enzyme-inhibition, or signaling pathway data specific to furosin has been published. Any attribution of mechanisms involving NF-κB modulation, antioxidant enzyme upregulation, or receptor agonism would be speculative in the absence of in vitro, in vivo, or clinical trial data.
As of the available scientific record, no human clinical trials, randomized controlled studies, observational cohort studies, or case reports have been published evaluating furosin in any therapeutic context. A search of PubMed and major biomedical databases yields no identified studies with quantified outcomes, sample sizes, or dosing protocols for this compound. No in vitro cell-culture studies or animal model experiments with documented endpoints have been attributed specifically to furosin in indexed literature. The current evidence base does not support any efficacy claims, and this compound remains scientifically uncharacterized at the clinical level.
No safety profile, toxicology data, or adverse event reporting exists for furosin in humans or animal models based on available indexed literature. Drug interaction potential, including effects on cytochrome P450 isoenzymes such as CYP3A4 or CYP1A2, has not been studied, making co-administration with pharmaceuticals an unknown risk. Pregnancy and lactation safety cannot be assessed due to the complete absence of reproductive toxicology data. Until peer-reviewed safety studies are conducted, consumption of furosin-containing supplements should be approached with caution and discussed with a qualified healthcare provider.
